Navigation Links
S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
Date:12/1/2008

SINGAPORE, Dec. 1 /PRNewswire/ -- S*BIO Pte Ltd today announced the initiation of a Phase 1/2 clinical trial of SB1518, a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF).

The trial is designed to evaluate the safety and tolerability of SB1518 in patients with CIMF and is expected to enrol up to 50 patients. The Phase 1 part of the study will assess the safety profile and evaluate the pharmacokinetic and pharmacodynamic activities of SB1518, and the Phase 2 component will assess the clinical benefits and continue to evaluate the safety profile of SB1518. The principal investigators are Dr. Andrew Roberts at the Royal Melbourne Hospital and Dr. John Seymour at the Peter MacCallum Cancer Centre.

"We are pleased with the advancement of our JAK2 inhibitor into a Phase 1/2 clinical trial in Australia as it exemplifies the expansion of our company's global development strategy," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "SB1518's strengths are in its exciting anti-proliferative and anti-tumor activity, as demonstrated by a range of in vitro and in vivo models, as well as its excellent tolerability. We believe this compound may eventually provide oncologists with a much needed and improved option to treat patients suffering from CIMF."

CIMF is a serious progressive and chronic condition whereby scar tissue develops in the bone marrow, resulting in a reduced ability to produce sufficient blood cells. Consequently, more blood cells are made in other organs, such as the liver and spleen which are not as efficient at blood cell production as the bone marrow. CIMF is characterized by an enlarged spleen and progressive anaemia. Current therapies for CIMF are mostly palliative in nature and survival rates can be short. While the actual cause of the disease is unknown, the JAK2 gene has been implicated i
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. S*BIO Initiates U.S. Phase I Clinical Trials of Oral JAK2 Inhibitor SB1518 for the Treatment of Hematological Malignancies
2. S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
3. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
4. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
5. Anpath Group, Inc. Advances Relationship With the Washington Metropolitan Area Transit Authority (Metro)
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
9. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
10. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
11. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Kalifornien, 28. August 2014 ... Start der Patientenrekrutierung für eine IDE-Pivot-Studie ... zur Beurteilung der Sicherheit und Wirksamkeit ... Aneurysmen („WEB") bekanntgegeben. Adam Arthur, MD, Dozent ... of Neurosurgery/Semmes-Murphey Clinic, und Hauptprüfarzt der ...
(Date:8/28/2014)... ALISO VIEJO, Calif. , Aug. 28, 2014 ... has initiated patient enrollment in an Investigational Device ... and effectiveness of the WEB™ Aneurysm Embolization System ... University of Tennessee Department of Neurosurgery/Semmes-Murphey Clinic and ... first four patients in the study, treating them with ...
(Date:8/28/2014)... 28, 2014 GenSpera, Inc. (OTCQB: GNSZ), a ... cancer, announces the recent publication of the article "Targeting ... The recent article co-authored by Doan, et ... of GenSpera,s prodrug technology platform that is designed to ... plant Thapsia garganica ) directly to tumors. These ...
Breaking Medicine Technology:Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 2Sequent Medical kündigt Start einer IDE-Studie für das WEB System zur Embolisation von Aneurysmen bekannt 3Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 2Sequent Medical Announces Initiation Of IDE Study For The WEB Aneurysm Embolization System 3GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 2GenSpera Media Advisory; "Targeting thapsigargin towards tumors" Published in Steroids 3
... PARK, Ill., Oct. 20 Abbott has,received a ... Drug,Administration (FDA) for its New Drug Application (NDA) ... is,evaluating the FDA Complete Response Letter, will discuss ... update when appropriate., Abbott is seeking the ...
... Corporation,(Nasdaq: ALUS ), the worldwide leader in ... scientific,posters featuring both patient cases and laboratory research ... presented this week at the American,Society of Anesthesiologists ... Dr. Arie Blitz, Director of Heart Transplantation and ...
Cached Medicine Technology:Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 2Thermogard XP(TM) Studies to Be Presented at American Society of Anesthesiologists Annual Meeting 3
(Date:8/28/2014)... greater amounts of yellow pigment in your eyes could ... conditions, a new study reports. In a laboratory ... order to test the distance vision of people with ... in their eyes. The volunteers had widely varying ... nutrients lutein and zeaxanthin, according to the researchers, led ...
(Date:8/28/2014)... GreenRushReview.com, a website dedicated to ... “Video” section located at http://www.greenrushreview.com/category/videos/ , which ... cannabis companies in video format. In the site’s ... news clips, interviews, and other short videos discussing ... the videos can also be found on the ...
(Date:8/28/2014)... Alexandria, VA (PRWEB) August 28, 2014 ... Foundation) will interview Stephen Isaacs, the chairperson, president and ... the Foundation’s Meet the Mesothelioma Experts live ... Foundation’s executive director and mesothelioma expert nurse practitioner, ... the interview will be Aduro BioTech’s experimental therapy for ...
(Date:8/28/2014)... PreDiabetes Centers, the nation’s top provider of prediabetes ... help clients and online readers send out summer healthfully ... Ashley developed variations of Roasted Veggie Pizza , ... PreDiabetes Centers Roasted Veggie Pizza recipe is made with ... a cheese substitute–ideal for people who are lactose intolerant ...
(Date:8/28/2014)... 2014 veEDIS Clinical Systems, LLC ... System (EDIS), in Lawrence Medical Center, located in ... to document patient care, veEDIS is a key ... well as the authorized, confidential exchange of patient ... veEDIS technology, designed in accordance with clinical workflows ...
Breaking Medicine News(10 mins):Health News:Eye Pigment May Help Vision in Hazy Conditions 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 2Health News:Emerging Cannabis Industry Website GreenRushReview.com Adds a Featured Video Section to Cover Marijuana Business Sector News 3Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 2Health News:New Clinical Trial: Using the Listeria Virus to Fight Mesothelioma 3Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 2Health News:PreDiabetes Centers Concierge Chef Creates Tasty Grilled Veggie Pizza Recipes for Labor Day Party Menu 3Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 2Health News:veEDIS Clinical Systems “Delivers,” as the 2014 Edition CEHRT Emergency Department EHR System is Implemented at Lawrence Medical Center 3
... COPD or chronic obstructive pulmonary disease is a ... // and is associated with severe emphysema or ... can reduce the mortality rate and number of ... study conducted by researchers from the University of ...
... say transmission of genital herpes to others is the ... study shows //the drug valacyclovir may significantly reduce the ... more than 1,400 heterosexual couples. In each case, one ... other was susceptible to the virus. Type 2 herpes ...
... change the way doctors treat certain prostate cancer patients.The ... cancer patient are grade, PSA level and pathologic stage. ... the Gleason grading system or a Gleason score (GS). ... cancer is seven. In a new study, researchers look ...
... A new study shows the drug valacyclovir may significantly ... more than 1,400 heterosexual couples. In each case, one ... other was susceptible to the virus. Type 2 herpes ... contagious. Participants with herpes were given ...
... since it interferes with eating and drinking. Children are ... the importance of maintaining// their normal fluid intake despite ... tonsillectomy procedure using less energy than the standard electrocautery ... ,During a tonsillectomy using the electrocautery method, a ...
... by researchers say it is a misconception to believe ... housebound people.// ,Researchers examined 150 children and ... vitamin D. Among the participants, all African-American, East African, ... as were all patients younger than 30. Five patients ...
Cached Medicine News:
Antigenic Free Protein S, ELISA Method...
... Assay for the Quantitative ... Protein S level based ... Va Inhibition by STA© ... free of Protein S; ...
Colorimetric Assay of Protein C Activity by STA© Analyzers. Highly purified extract of Agkistrodon c. contortrix venom for specific activation of protein C, with an activator selected specially ...
Colorimetric Assay of Antithrombin III Activity by STA© Analyzers. Bovine thrombin ~12NIH units/mL, freeze-dried....
Medicine Products: